Home Newsfeeds HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.

byBenzinga Newsdesk

March 13, 2023

1 minute read

HC Wainwright & Co. analyst Joseph Pantginis reiterates Clene (NASDAQ:CLNN) with a Buy and maintains $15 price target.

Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Results From Solid Tumor Study Of LYMPHIR In Combination With Checkpoint Inhibitor

By Benzinga Newsdesk

October 31, 8:47 AM

Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor

CTXR

Wynnefield Capital Compelled To Send Open Letter To TechPrecision Board; Demands Techprecision Hold Public Conference Call To Explain Proposed Acquisition Of Votaw Precision Technologies To Stockholders

By Benzinga Newsdesk

December 7, 9:19 AM

Wynnefield Capital and its affiliates, collectively the largest institutional stockholder of TechPrecision Corporation (NASDAQ:TPCS), with a 4.5% beneficial ownership interest, today issued the following public letter to

TPCS

ImmixBio Ships Tislelizumab For Patient Dosing In Its Combination Clinical Trial With IMX-110 In Advanced Solid Tumors

By Benzinga Newsdesk

December 19, 9:01 AM

Tislelizumab supplied by BeiGene as part of ImmixBio's Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors IMX-110 + Tislelizumab clinical trial

IMMX

Telsey Advisory Group Maintains Outperform on Dollar Gen, Raises Price Target to $285

By Benzinga Newsdesk

August 26, 4:39 AM

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Gen (NYSE:DG) with a Outperform and raises the price target from $280 to $285.

HC Wainwright & Co. Reiterates Buy on Clene, Maintains $15 Price Target

Related Posts

Citius Pharmaceuticals Announces Publication In Frontiers Of Immunology Of Results From Solid Tumor Study Of LYMPHIR In Combination With Checkpoint Inhibitor

Wynnefield Capital Compelled To Send Open Letter To TechPrecision Board; Demands Techprecision Hold Public Conference Call To Explain Proposed Acquisition Of Votaw Precision Technologies To Stockholders

ImmixBio Ships Tislelizumab For Patient Dosing In Its Combination Clinical Trial With IMX-110 In Advanced Solid Tumors

Telsey Advisory Group Maintains Outperform on Dollar Gen, Raises Price Target to $285